Test Blog

Degelis Pilla, CFA CEO and Co-Founder

🕒 1 Min. Read

📅 September 22, 2026

CBC (cannabichromene) is one of the “big six” cannabinoids found in cannabis alongside THC, CBD, CBG, CBN, and CBT. It’s non-psychoactive, it has some of the strongest preclinical anti-inflammatory data of any minor cannabinoid, and as of April 2026, zero human clinical trials have tested it. Everything published lives in animal models (mostly mice and rats) and in vitro cell studies. That doesn’t make the research worthless. It makes it directionally useful while requiring honest framing. This guide walks through every researched effect of CBC with the specific primary sources, sample sizes where applicable, and what the results actually show vs what marketing claims.

Degelis Pilla, CFA
CEO and Co-Founder

Degelis (“Dege,” pronounced “Dayj”) launched TribeTokes in 2017 after identifying a specific problem in the cannabis vaping market: most products were made with cutting agents and additives that had no place in a wellness brand. She built TribeTokes from zero into a multi-million dollar DTC brand with over 100,000 customers, a full cannabinoid product catalog, and a loyal wholesale retail network.

Degelis is an active member of the Entrepreneurs’ Organization and a regular voice in both the cannabis and women-in-business spaces. She is a CFA charterholder (Chartered Financial Analyst), and holds her undergraduate business degree from the University of Virginia.